Many biomarkers have been assessed for ability to predict malignant transformation (development of squamous carcinoma) in oral potentially malignant disorders (OPMDs). Two are supported by a significant body of evidence from follow-up and prospective studies and clinical trials: aneuploidy and loss of heterozygosity (Nikitakis et al., 2018). Aneuploidy is a change from the normal DNA or chromosomal complement in a cell and is assessed by either detecting specific chromosomal amplifications and deletions or non-specifically by measuring total cell DNA content (Danielsen et al., 2016). Loss of heterozygosity (LOH) is the loss of one of pair of alleles at a constitutional heterozygous locus and is assessed by detecting small DNA sequence changes at specific chromosomal loci, usually near tumour suppressor genes (Thiagalingam et al., 2001). Despite their different biological bases, both techniques are markers of relatively large genetic changes and chromosomal instability. This is because the highly sequence-specific LOH changes detected reflect much larger DNA changes including deletions, whole chromosome loss, unbalanced rearrangements, abnormal recombination or acquired uniparental disomy (Makishima & Maciejewski, 2011). Thus, although these methods appear very different, both reflect chromosomal instability and aneuploidy. Chromosomal instability (duplication or deletion of chromosomes or parts of chromosomes) and genomic instability (changes in DNA sequence, microsatellite (stretches of DNA short tandem repeats with high mutation rate) or chromosomal structure) are